Research points to why some colorectal cancers recur after treatment

Cetuximab, marketed as Erbitux®, is one of the key therapies for metastatic colorectal cancer. Yet the cancer still returns in some patients, shortening overall survival.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news